cigna glp-1 2025 will stop covering weight-loss drugs including Wegovy and Zepbound in its ​employee health plan effective July 1, according to Reuters cigna glp-1 2025 Cigna is

Thats where tools lik

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

Note: Anti-Obesity GLP-1s Wegovy and Zepbound, Anti-Diabetes GLP-1s Ozempic and Mounjaro Source: IQVIA MAAS Patient Behavior Library Tool

By early 2025, nearly 25% of diabetes patients had started a GLP1 therapy, up from just 3% four years ago

The program enables qualified patients to complete assessments from home while receiving guidance on medica

Signaling between the gut and the brain involves a complex mix of nutrients, peptides, and microbes that could be targeted as therapies for obesity and diabetes